1. Antibody response to Pneumocystis jirovecii major surface glycoprotein.
- Author
-
Daly, Kieran R., Huang, Laurence, Morris, Alison, Koch, Judy, Crothers, Kristina, Levin, Linda, Eiser, Shary, Satwah, Supriya, Zucchi, Patrizia, Walzer, Peter D., and Zucchi, Patricia
- Subjects
- *
LUNG diseases , *PNEUMONIA , *GLYCOPROTEINS , *HIV infections , *PNEUMOCYSTIS pneumonia , *HIV infection complications , *COMPARATIVE studies , *ENZYME-linked immunosorbent assay , *FUNGI , *IMMUNOGLOBULINS , *RESEARCH methodology , *MEDICAL cooperation , *PROTEINS , *RESEARCH , *RESEARCH funding , *AIDS-related opportunistic infections , *EVALUATION research , *MEMBRANE glycoproteins - Abstract
We conducted a prospective pilot study of the serologic responses to overlapping recombinant fragments of the Pneumocystis jirovecii major surface glycoprotein (Msg) in HIV-infected patients with pneumonia due to P. jirovecii and other causes. Similar baseline geometric mean antibody levels to the fragments measured by an ELISA were found in both groups. Serum antibodies to MsgC in P. jirovecii patients rose to a peak level 3-4 weeks (p<0.001) after recovery from pneumocystosis; baseline CD4+ count > or =50 cells/microL and first episode of pneumocystosis were the principal host factors associated with this rise (both p<0.001). Thus, MsgC shows promise as a serologic reagent and should be tested further in clinical and epidemiologic studies. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF